Fulvestrant (selective estrogen degrader (SERD)) and tamoxifen (selective estrogen receptor modulator (SERM)) are two additional endocrine deprivation therapies that mediate estrogen receptor antagonism and have been shown to promote immunogenic modulation in triple-negative breast cancer [176]. Here, ESR1 is linked to triple-negative breast carcinoma.